Market Overview

Morgan Stanley Sees Execution Priced In For Becton, Dickinson and Co.

Share:
Related BDX
Earnings Scheduled For May 5, 2016
UPDATE: BD Announces Divestment of Vertebral Augmentation Solutions Business to Stryker; Terms Not Disclosed

In a report published Tuesday, Morgan Stanley analyst David R. Lewis reiterated an Equal-Weight rating on Becton, Dickinson and Co. (NYSE: BDX).

In the report, Morgan Stanley noted, “Recent meetings stressed confidence in ~5% sales growth and greater leverage in FY15. BD continues to express interest in larger deals, though <$1B is more likely in our view. Inversions are possible but limited targets suggest less probable. At 17x CY15 EPS, execution is priced in; remain EW.”

Becton, Dickinson and Co. closed on Monday at $118.30.

Latest Ratings for BDX

DateFirmActionFromTo
Feb 2016Deutsche BankUpgradesHoldBuy
Feb 2016CitigroupMaintainsNeutral
Jan 2016Evercore ISI GroupDowngradesBuyHold

View More Analyst Ratings for BDX
View the Latest Analyst Ratings

Posted-In: David R. Lewis Morgan StanleyAnalyst Color Reiteration Analyst Ratings

 

Related Articles (BDX)

View Comments and Join the Discussion!